⭐️What to look 👀 for in your urine for cancer? Honored to film this public announcement for cancer awareness @BladderCancerUS @WorldBladderCan @IBCG_BladderCA @AmericanCancer #PatientCare #Healthcare #CancerAwareness #KnowledgeCanDiminishFear

RT @niklas_kluemper: More evidence that NECTIN4 matters as a biomarker for EV+pembrolizumab! 🎯 Important independent validation from @Matt…

Sunny San Diego ☀️, top GU oncologists, sunset sailing & dinner at Seaport Village ⛵️🍷 = unmatched! 🌅 @OncLive’s Bridging the Gaps in GU Cancers was brilliantly co-chaired by Dr. Tanya Dorff & Dr. Rana McKay! Thoughtful discussions collaborating on updated GU data to tackle key clinical & operational unmet needs in community oncology & urology! 🩺🌊 @TDorffOnc @DrRanaMcKay @OncHahn @neerajaiims @HHammersMD @katy_beckermann @BradMcG04 @YuWeiChenMD @DrRosenbergMSK @PGrivasMDPhD @DrVaishampayan @omgitsyuliaz @oncodaily

Is surgery becoming the adjuvant step in colorectal cancer? In this episode of #OncologyUnplugged 🔌, @CParkMD, and @pashtoonkasi, unpack neoadjuvant immunotherapy, from NICHE to NEST, dMMR to MSS, and ctDNA as an emerging end point. 🎧 onclive.com/view/neoadjuvant… #crcsm

Congrats to my dear friend @SagarLonialMD who received the Waldenstrom Lifetime Achievement Award for his incredible contributions to the myeloma field at the International Myeloma Society Annual Meeting in Glasgow yesterday. #IMS26 @Myeloma_Society

Bridging the Gaps lives up to its name including med onc, urology, rad onc, academic, and community represented. 📊 Bladder cancer Delphi consensus: 300 clinicians, 92% agreement that multidisciplinary care should look the same at an academic center and a community practice. Emphasis on need for multiD care tumor board, clinic, and care coordination. #GUonc #BTG2026 #MultidisciplinaryCare

Proud to be included in the 2026 @JCO_ASCO Acknowledgment of Reviewers Grateful for the opportunity to contribute #PeerReview #JCO

🩸 CML HAS CHANGED. HAVE OUR TREATMENT ALGORITHMS KEPT UP? The era of simply choosing a TKI and monitoring response is behind us. Today, treating chronic myeloid leukemia means navigating an increasingly complex set of decisions: Which TKI should you start — and for whom? When should an inadequate response trigger a switch? How should resistance mutations change treatment selection? Where do newer agents fit into sequencing? Who can safely pursue treatment-free remission — and when? At this week's MedNews Week Keynote Conference, we go directly into these questions with Dr. Jorge Cortes, MD, one of the investigators who helped build the evidence base behind modern CML therapy. 🎙️ THE CML EVOLUTION: Mastering Modern Algorithms in Chronic Myeloid Leukemia Dr. Cortes breaks down how CML management has evolved and, more importantly, how to translate that evolution into real-world treatment decisions at the bedside. Now at the University of Alabama at Birmingham, Dr. Cortes has led 90+ Phase I–III clinical trials, authored 1,000+ scientific publications, abstracts, and academic contributions, and held major international leadership roles in CML—including leadership of the International Chronic Myeloid Leukemia Foundation. This isn't just a review of CML. It is an opportunity to learn how one of the field's most influential investigators thinks through the decisions that define modern CML care. 📅 September 16, 2026 ⏰ 12:30 PM ET 🌎 MedNews Week Keynote Conference Catch this episode exclusively on OncoDaily TV: piped.video/watch?v=dtWA2bQ2… From first-line therapy → resistance → sequencing → treatment-free remission. If you treat leukemia—or are training to—this is one conversation worth hearing. MedNews Week | Connecting Medicine Globally. #MedNewsWeek #CML #ChronicMyeloidLeukemia #Leukemia #Hematology #HemeOnc #Oncology #CancerResearch #CancerCare #ClinicalOncology #PrecisionMedicine #TargetedTherapy #TKI #TreatmentFreeRemission #ClinicalTrials #MedicalEducation #HematologyOncology #OncTwitter #MedTwitter #ConnectingMedicineGlobally @oncodaily

Today, 5 years ago, I started my US journey. I can’t overstate the impact this country and DFCI had on my trajectory. I felt welcome, grew tremendously as a physician and scientist. Grateful for the people and trust that shaped these years. Looking forward to what comes next!

A pleasure to join the panel at the @kyscocancer KYSCO Fall Oncology Review to discuss metastatic prostate cancer! Especially enjoyed sharing the stage with @CParkMD —always appreciate his insights and encouragement.

Am honored to accept the Baklava award by @chadinabhan during #BGT2026 meeting! We went together with Chadi, @BrainTumorDoc @VivekSubbiah to find baklava Friday night while @BalazsHalmosMD was preparing his debate slides? I am reassuring @LeonidasPlatan1 about supporting walnuts

10 new @FDA indications in #bcsm in 20 weeks - May to September, 2026. Three firsts in there: first PROTAC in any cancer, first CDK4/6 inhibitor in HER2+ #bcsm, first drug approval triggered by ctDNA prior radiographic progression. #clinicaltrials win! Patients win!

🎙️ On this #OncologyUnplugged episode, @CParkMD, of @Norton_Health, and @JoshuaBrodyMD, of @TischCancer, note evolving treatments for B-cell lymphomas. #lymsm #hematology Watch the episode on our site or listen on your favorite podcast platforms: onclive.com/view/fast-moving…

🔥Multi-omic profiling enables recurrence risk stratification beyond pathological stage in resected EGFR-mutant LUAD 🆙 @JTOonline ☑Genomic instability, TP53 co-mutations & transcriptomic features profiled 🎯Multi-omic model C-index 75.4% across 4 validation cohorts 🎯High vs Low Risk in Stage I: IA HR 12.53, IB HR 18.10 🎯Benefit by Adjuvant TKI: Low Risk➖ High Risk➕ 🎙 @stephanieplsaw @danieltanmd #LCSM @OncoAlert @Larvol @EGFRResisters jto.org/article/S1556-0864(2…

Dr. @CParkMD at #WorldGU25 made the case that mHSPC now needs care guided by genetic mutation signatures. His take on KIM-1, ctDNA, and how we counsel patients when tests are positive is the kind of practical teaching #WorldGU26 is built around. Join leading GU experts December 3–5, 2026, in Nashville. Free registration is live: ow.ly/aLA550ZMIRl #GUOncology #MedEd #ThrowbackThursday

#WCLC26 was a truly global 🌎 meeting . Where else could you meet lung cancer experts from Spain, Mexico, Colombia, Puerto Rico, Canada and Nepal all in one day. @AnaVManana @Tony_Calles @RamilaShilpakar @mgonzalezvelMD @JorgeAlatorreA1 Dr Marc de Perrot

Ever wonder how heterogeneity defines bladder cancer subtypes? Ha and Hsieh Lab postdoctoral fellows @pushpa_itagi and Samantha Schuster @fredhutch did, leading to a deep study of bladder cancer clonality, evolution, and heterogeneity published @Nature nature.com/articles/s41586-0…

A pleasure to welcome Dr @NicosiaMd to our Radiation Oncology departments in Madrid and show him our Clinical Trials Unit and MRIdian® MR-Linac programme. A great opportunity to share experiences and strengthen international collaboration. Thank you, Luca! #RadiationOncology

Thanks @BladderCancerUS for partnering in important mission to understand better, prevent, diagnose earlier & cure bladder cancer and support patients & caregivers! @HsiehLab @GavinHa @DrOmarMian @OncoAlert @fredhutch @uwmnewsroom @Uromigos @HutchPresident @spsutkaMD @VenurVyshak

Expanding our Team to 🇪🇸 and 🇺🇦 with residents and students in collaboration with @docjavip @Maroto5Pablo @HospitalSantPau @SanRaffaeleMI @MyUniSR #VladyKasyanenko @MariaCotainaMD #SilviaReparaz #Madrid #Barcelona #Clasico in Milan All of them put under @MyUniSR DNA!